6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $34M | -$47M | 0.0% | -141.1% | -$32M | $19M | $20M |
| 2024 | $28M | -$47M | 0.0% | -178.0% | -$46M | $0 | $17M |
| 2023 | $23M | -$52M | 0.0% | -251.2% | -$47M | — | $24M |
| 2022 | $17M | -$61M | 0.0% | -369.0% | -$65M | $0 | $27M |
| 2021 | $23M | -$74M | 0.0% | -203.3% | -$58M | $0 | $178M |
| 2020 | $16M | -$37M | 0.0% | -190.0% | -$32M | $25M | $30M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $8M | -$14M | 4.6% | -173.1% | -$15M | $19M | $14M |
| Dec '25 | $11M | -$12M | 0.0% | -108.2% | -$3M | $19M | $20M |
| Sep '25 | $8M | -$12M | 0.0% | -145.1% | -$9M | $19M | $19M |
| Jun '25 | $7M | -$12M | 0.0% | -167.3% | -$10M | — | $18M |
| Mar '25 | $7M | -$11M | 5.6% | -161.8% | -$9M | — | $19M |
| Dec '24 | $8M | -$10M | 0.0% | -124.5% | -$10M | $0 | $17M |
| Sep '24 | $8M | -$11M | 0.0% | -158.3% | -$9M | — | $22M |
| Jun '24 | $7M | -$13M | 0.0% | -202.1% | -$11M | — | $37M |
| Mar '24 | $6M | -$13M | 0.0% | -254.4% | -$16M | — | $22M |
| Dec '23 | $6M | -$11M | 0.0% | -192.3% | -$10M | — | $24M |
| Sep '23 | $6M | -$13M | 0.0% | -235.1% | -$10M | — | $24M |
| Jun '23 | $5M | -$14M | 0.0% | -301.0% | -$9M | — | $29M |
| Mar '23 | $5M | -$14M | 0.0% | -295.4% | -$17M | — | $24M |
| Dec '22 | $4M | -$16M | 0.0% | -394.6% | -$12M | $0 | $27M |
| Sep '22 | $5M | -$16M | 0.0% | -356.3% | -$17M | $0 | $26M |
| Jun '22 | $4M | -$13M | 0.0% | -364.6% | -$17M | $0 | $50M |
| Mar '22 | $4M | -$15M | 0.0% | -360.6% | -$19M | $0 | $63M |
| Dec '21 | $5M | -$15M | 0.0% | -279.5% | -$15M | $0 | $178M |
| Sep '21 | $7M | -$25M | 0.0% | -175.7% | -$20M | — | $220M |
| Jun '21 | $6M | -$12M | 0.0% | -177.2% | -$12M | $25M | $100M |
How the market has priced RPID against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, RAPID MICRO BIOSYSTEMS, INC.'s revenue has grown 15.9% per year. These are computed facts, not advice.
As of FY2025, RAPID MICRO BIOSYSTEMS, INC. reported $19M of total debt against $20M of cash; operating income covered interest expense -43.5×.
In FY2025, gross margin was —, operating margin -141.1%, and net margin -140.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.